ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Bilirubin as a Modulator of WNK1 Protein Signaling: Implications for Neuroinflammatory Diseases.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Previously regarded merely as a potentially harmful waste product of heme catabolism, bilirubin has now emerged as a pleiotropic molecule with potent antioxidant, anti-inflammatory, and hormone-like properties. Recent findings have revealed protective effects against cardiovascular, metabolic, autoimmune, and neoplastic diseases, as well as neurological disorders. The growing understanding of neuroinflammatory processes has opened new avenues for exploring the role of bilirubin in neuroprotection. Despite the increasing number of studies investigating the protective effects of bilirubin in neurological diseases, the molecular mechanisms underlying its anti-inflammatory actions in the brain remain insufficiently understood. In this perspective article, With-No-Lysine (K) kinase 1 (WNK1) is discussed as a newly identified molecular target of bilirubin, highlighting its potential implications for neuroinflammatory diseases. The bilirubin-WNK1 axis may represent a previously unrecognized protective mechanism that could be leveraged to mitigate inflammation-driven neurodegeneration. This interaction can open new therapeutic opportunities for neurodegenerative disorders such as multiple sclerosis (MS), Alzheimer's disease, and Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.